Cargando…

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

INTRODUCTION: In a previous pooled analysis of 19 double-blind clinical studies conducted by Merck, which included data available as of July 2009 on 10,246 patients with type 2 diabetes (T2DM), treatment with sitagliptin was shown to be generally well tolerated compared with treatment with control a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engel, Samuel S., Round, Elizabeth, Golm, Gregory T., Kaufman, Keith D., Goldstein, Barry J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687098/ https://www.ncbi.nlm.nih.gov/pubmed/23700194 http://dx.doi.org/10.1007/s13300-013-0024-0

Ejemplares similares

Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
por: Engel, Samuel S., et al.
Publicado: (2013)

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
por: Williams-Herman, Debora, et al.
Publicado: (2010)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
por: Williams-Herman, Debora, et al.
Publicado: (2008)

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
por: Arjona Ferreira, Juan Camilo, et al.
Publicado: (2013)

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2016)

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine
por: Mathieu, Chantal, et al.
Publicado: (2015)

Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
por: Ommen, Elizabeth S., et al.
Publicado: (2015)

Erratum to: Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
por: Ommen, Elizabeth S., et al.
Publicado: (2015)

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
por: Engel, S S, et al.
Publicado: (2010)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
por: Miller, Sam, et al.
Publicado: (2018)

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study
por: Roussel, Ronan, et al.
Publicado: (2018)

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
por: Raji, Annaswamy, et al.
Publicado: (2020)

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study
por: Dagogo‐Jack, Samuel, et al.
Publicado: (2017)

Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials
por: Raji, Annaswamy, et al.
Publicado: (2018)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
por: Tajima, Naoko, et al.
Publicado: (2019)

A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin
por: Seino, Yutaka, et al.
Publicado: (2021)

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study
por: Scott, Russell, et al.
Publicado: (2018)

A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes
por: Gantz, Ira, et al.
Publicado: (2017)

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
por: Pratley, Richard E., et al.
Publicado: (2018)

Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes
por: Ohmura, Hirotoshi, et al.
Publicado: (2015)

Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study
por: Frias, Juan P., et al.
Publicado: (2019)

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
por: Lee, Seung-Hwan, et al.
Publicado: (2017)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
por: Goldenberg, Ronald, et al.
Publicado: (2017)

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Kinduryte Schorling, Ona, et al.
Publicado: (2020)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604
por: Engel, Samuel S., et al.
Publicado: (2013)

Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes
por: Shankar, R Ravi, et al.
Publicado: (2016)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides
por: Tanaka, Tsuyoshi, et al.
Publicado: (2013)

Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
por: Ballav, Chitrabhanu, et al.
Publicado: (2013)

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
por: Kubota, Akira, et al.
Publicado: (2012)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Barnard, Karen, et al.
Publicado: (2010)

Efficacy and safety of metformin and sitagliptin‐based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study
por: Liu, Xiangyang, et al.
Publicado: (2020)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh, Ching-Jung, et al.
Publicado: (2014)

Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
por: Fukuda, Masahiro, et al.
Publicado: (2018)

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
por: Kohler, Sven, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5ck0cku850n84mkn12teoamjeo